A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

Vaccine

Volumn 27, Issue 43, 2009, Pages 6088-6094

  Gandhi, Rajesh T ^a   O'Neill, David ^b   Bosch, Ronald J ^c   Chan, Ellen S ^c   Bucy, R Pat ^d   Shopis, Janet ^a   Baglyos, Lynn ^e   Adams, Elizabeth ^f   Fox, Lawrence ^f   Purdue, Lynette ^f   Marshak, Ann ^g   Flynn, Theresa ^a   Masih, Reena ^f   Schock, Barbara ^h   Mildvan, Donna ^g   Schlesinger, Sarah J ⁱ   Marovich, Mary A ^j   Bhardwaj, Nina ^b   Jacobson, Jeffrey M ^k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e SANOFI PASTEUR   (France)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g BETH ISRAEL MEDICAL CENTER   (United States)

^h Frontier Science ^*  (United States)

ⁱ ROCKEFELLER UNIVERSITY   (United States)

^j Walter Reed Army Institute   (United States)

^k DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Canarypox; Clinical trial; Dendritic cells; HIV 1; Therapeutic vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; KEYHOLE LIMPET HEMOCYANIN;

ADULT; ANIMAL CELL; ARTICLE; CANARYPOX VIRUS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG WITHDRAWAL; EMBRYO; ENZYME LINKED IMMUNOSPOT ASSAY; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MALE; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; VIREMIA; VIROLOGY; VIRUS LOAD;

ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; CANARYPOX VIRUS; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 70349299844     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.016     Document Type: Article

References (34)

1. Walsh S.R.B.N., and Gandhi R.T. Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Current HIV Reports (2003) 205-216
2. O'Neill D.W., and Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infections. Mol Biotechnol 36 (2007) 131-141
3. Russell N.D., Graham B.S., Keefer M.C., McElrath M.J., Self S.G., Weinhold K.J., et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44 (2007) 203-212
4. Fleury B., Janvier G., Pialoux G., Buseyne F., Robertson M.N., Tartaglia J., et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 174 (1996) 734-738
5. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 177 (1998) 1230-1246
6. Evans T.G., Keefer M.C., Weinhold K.J., Wolff M., Montefiori D., Gorse G.J., et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 180 (1999) 290-298
7. Jin X., Ramanathan Jr. M., Barsoum S., Deschenes G.R., Ba L., Binley J., et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 76 (2002) 2206-2216
8. Jacobson J.M., Pat Bucy R., Spritzler J., Saag M.S., Eron Jr. J.J., Coombs R.W., et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 194 (2006) 623-632
9. Kinloch-de Loes S., Hoen B., Smith D.E., Autran B., Lampe F.C., Phillips A.N., et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192 (2005) 607-617
10. Autran B., Murphy R.L., Costagliola D., Tubiana R., Clotet B., Gatell J., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). Aids 22 (2008) 1313-1322
11. Gandhi R.T., and Altfeld M. The quest for an HIV-1 therapeutic vaccine. J Infect Dis 192 (2005) 556-559
12. Kilby J.M., Bucy R.P., Mildvan D., Fischl M., Santana-Bagur J., Lennox J., et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 194 (2006) 1672-1676
13. Engelmayer J., Larsson M., Lee A., Lee M., Cox W.I., Steinman R.M., et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 75 (2001) 2142-2153
14. Deeks S.G., and Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27 (2007) 406-416
15. Tartaglia J., Benson J., Cornet B., Cox W., El Habib R., Excler J., et al. In: Girard M., and Dodet B. (Eds). Potential improvements for poxvirus-based immunization vehicles. Onzieme Colloque des Cent Grades (1997), Pasteur Merieux, Marnes-La-Coquette, Paris, France 187-197
16. Marovich M.A., Mascola J.R., Eller M.A., Louder M.K., Caudrelier P.A., El-Habib R., et al. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J Infect Dis 186 (2002) 1242-1252
17. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104 (1999) 173-180
18. Dhodapkar M.V., Krasovsky J., Steinman R.M., and Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105 (2000) R9-R14
19. Franchini G., Gurunathan S., Baglyos L., Plotkin S., and Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vac 3 (2004) S75-88
20. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192 (2005) 1249-1259
21. Coombs R.W., Speck C.E., Hughes J.P., Lee W., Sampoleo R., Ross S.O., et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 177 (1998) 320-330
22. Adams S., O'Neill D.W., Nonaka D., Hardin E., Chiriboga L., Siu K., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181 (2008) 776-784
23. Lederman M.M., Connick E., Landay A., Kuritzkes D.R., Spritzler J., St Clair M., et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 178 (1998) 70-79
24. Yusim K., Kesmir C., Gaschen B., Addo M.M., Altfeld M., Brunak S., et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol 76 (2002) 8757-8768
25. Lichterfeld M., Kaufmann D.E., Yu X.G., Mui S.K., Addo M.M., Johnston M.N., et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 200 (2004) 701-712
26. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 (2007) 1405-1416
27. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
28. Connolly N.C., Whiteside T.L., Wilson C., Kondragunta V., Rinaldo C.R., and Riddler S.A. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 15 (2008) 284-292
29. Garcia F., Lejeune M., Climent N., Gil C., Alcami J., Morente V., et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 191 (2005) 1680-1685
30. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10 (2004) 1359-1365
31. Kavanagh D.G., Kaufmann D.E., Sunderji S., Frahm N., Le Gall S., Boczkowski D., et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 107 (2006) 1963-1969
32. Melhem N.M., Liu X.D., Boczkowski D., Gilboa E., and Barratt-Boyes S.M. Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. Eur J Immunol 37 (2007) 2164-2173
33. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118 (2008) 1427-1436
34. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., and Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14 (2008) 617-621